In average-risk individuals, ColoSense demonstrated 93% sensitivity for detecting colorectal cancer (CRC) and 45% sensitivity for detecting advanced adenomas (AA). The CRC-PREVENT study evaluated more ...

ST. LOUIS, July 24, 2025--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, received FDA approval to ...

New recommendations from the American Cancer Society include blood-based and updated at-home tests as colon cancer screening ...

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced the publication of a ...

Two-step screen + RT-qPCR validation yields AUC 0.94 (CRC) and 0.83 (advanced adenoma) in 114-sample pilot PLEASANTON, Calif., Aug. 25, 2025 /PRNewswire/ -- A peer-reviewed study published in ...

Novel first-generation cell-free DNA blood (cf-bDNA) tests for colorectal cancer (CRC) cost more and are less effective than colonoscopy or stool tests, a new analysis suggests. Researchers estimated ...

ORLANDO -- Patients with inflammatory bowel disease (IBD) reported mostly favorable responses with the use of mail-order kits for stool sample collections, according to a survey study. Among survey ...